[oncokb] Newest OncoKB updates: June 6, 2022

[Contact OncoKB]

Dear OncoKB user,

Here are the latest OncoKB updates:

June 6, 2022Data version: v3.14

• Changed Annotation:

  Gene	Mutation	Cancer Type	Drug(s)	Previous Level	Current Level	Reason
  BRAF	V600E	Biliary Tract Cancer	Dabrafenib + Trametinib	3A	2	Listing in Hepatobiliary NCCN v1.2022; PMID: 32818466, 32758030

• Updated therapeutic implications: - Additional therapies for variants

  Gene	Mutation	Cancer Type	Current Level of Evidence	Drug(s) Already in OncoKB™	Newly Added Drug	Evidence
  ALK	Fusions	Inflammatory Myofibroblastic Tumor	2	Crizotinib, Ceritinib, Brigatinib	Lorlatinib (Level 2)	Listing in Soft Tissue Sarcoma NCCN v1.2022; PMID: 28713152, 32868646, 33007314
  ROS1	Fusions	Non-Small Cell Lung Cancer	1	Crizotinib, Entrectinib	Repotrectinib (Level 3A)	FDA breakthrough therapy designation; Abstract: Cho et al. Abstract# MA11.07, IASLC 2021
  NTRK1, NTRK2, NTRK3		All Solid Tumors		Larotrectinib, Entrectinib

As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you.

--

The OncoKB Team